- A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases(2023)
Auteurs: Wannee Kantasiripitak, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
Pagina's: 896 - 908
- Model-informed precision dosing of infliximab to improve outcomes of individual patients with inflammatory bowel diseases(2023)
Auteurs: Wannee Kantasiripitak, Erwin Dreesen, Marc Ferrante, Debby Thomas
- Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases(2022)
Auteurs: Wannee Kantasiripitak, Alex Kensert, Zhigang Wang, João Guedelha Sabino, Séverine Vermeire, Debby Thomas, Marc Ferrante, Erwin Dreesen
Pagina's: 1045 - 1059
- Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases(2021)
Auteurs: Wannee Kantasiripitak, Zhigang Wang, Isabel Spriet, Marc Ferrante, Erwin Dreesen
Pagina's: 1455 - 1466
- The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases(2021)
Auteurs: Wannee Kantasiripitak, Bram Verstockt, Dahham Alsoud, Debby Thomas, Séverine Vermeire, Marc Ferrante, Erwin Dreesen
Pagina's: 3776 - 3789
- Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?(2020)
Auteurs: Wannee Kantasiripitak, Ruth Van Daele, Matthias Gijsen, Marc Ferrante, Isabel Spriet, Erwin Dreesen
- A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis(2020)
Auteurs: Erwin Dreesen, Wannee Kantasiripitak, Séverine Vermeire, Marc Ferrante, Thomas Bouillon, Ann Gils
Pagina's: 570 - 580
